Savara(US:SVRA) Newsfile·2025-11-08 02:43Core Viewpoint - Rosen Law Firm is reminding investors of Savara Inc. (NASDAQ: SVRA) about the November 7, 2025 deadline to join a securities class action lawsuit related to the company's alleged misleading statements during the class period from March 7, 2024, to May 23, 2025 [1][2]. Group 1: Class Action Details - Investors who purchased Savara securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by the November 7, 2025 deadline [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Allegations Against Savara Inc. - The lawsuit alleges that Savara made false and misleading statements regarding the MOLBREEVI Biologics License Application (BLA) for a treatment of a rare lung disease, including insufficient information on its chemistry and manufacturing [5]. - It is claimed that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which could delay Savara's submission timeline and increase the need for additional capital [5]. - The lawsuit asserts that these misleading public statements resulted in investor damages when the true information became known [5].